PARP1 and colorectal carcinoma: Accordingly, we find that MEKi synergize with poly ADP-ribose polymerase 1/2 (PARP1/2) inhibitors in reducing tumor cell viability, and the combination of these two agents can further enhance the effectiveness of radiotherapy in CRC cell lines, organoids, and murine xenograft models.